We’re proud to see ZeusOSA featured in the NIHR Annual Report 2025/26, highlighting ongoing research into the potential of our technology to offer a non-invasive approach for people living with obstructive sleep apnoea (OSA).
Exploring new approaches to obstructive sleep apnoea
Obstructive sleep apnoea is a common sleep disorder in which the airway repeatedly narrows or closes during sleep, interrupting breathing and affecting sleep quality.
One of the most widely used treatments for OSA is continuous positive airway pressure, commonly known as CPAP. While CPAP can be highly effective, some people find it difficult to tolerate or use consistently, creating a need to explore additional treatment options that may work for different patients.
This is where the research into ZeusOSA comes in.
The technology is based on the non-invasive stimulation approach behind Zeus, worn externally on the skin beneath the jaw. ZeusOSA is being developed and investigated specifically for its potential application in obstructive sleep apnoea.
From early research to NHS clinical trials
As highlighted by the NIHR, the technology has progressed from early-stage testing towards further evaluation through NIHR-funded clinical trials in NHS sleep centres, supported by the NIHR HealthTech Research Centre in Cardiovascular and Respiratory Medicine and the NIHR Research Delivery Network in South London.
The aim of this research is to build robust clinical evidence around the technology and explore whether this non-invasive approach could, in the future, provide an additional treatment option for people living with OSA.
For us, it represents an exciting next chapter in the development of the technology and our wider ambition to help improve sleep through innovation and clinical research.
Continuing to innovate in sleep health
Zeus was developed to provide a non-invasive approach to managing tongue and throat-based snoring. Seeing the underlying technology now being explored further through ZeusOSA demonstrates the potential for continued innovation within sleep medicine.
There is still important research to be completed, but we’re incredibly proud to see this work recognised by the NIHR and to be working alongside researchers and NHS sleep centres to investigate what the future could hold.
Read more about ZeusOSA and the research in the NIHR Annual Report 2025/26.
Please note: ZeusOSA is currently under clinical investigation and is not currently available as an approved treatment for obstructive sleep apnoea.
